ArticleActa diabetologica2026
Targeted metabolomics identifies associations of plasma ceramides and their ratios with incident type 2 diabetes mellitus.
Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsLimited studies explored the association between ceramides and the risk of type 2 diabetes mellitus (T2DM). We aimed to investigated whether plasma ceramides and their ratios to Cer(d18:1/16:0) would be associated with T2DM in Chinese adult residents.
methodsThis investigation was designed as a matched case-control study nested within a community-based longitudinal cohort in Suzhou, China. Plasma concentrations of eight ceramides (C16-C24) were measured quantitatively in 234 cases and 468 matched controls using high-throughput targeted lipidomics. Conditional logistic regression models were used to estimate odds ratios (ORs). We assessed the improvements in risk discrimination by net reclassification improvement (NRI) and integrated discrimination improvement (IDI).
resultsSeven ceramides (d18:1/16:0, d18:1/18:0, d18:1/20:0, d18:1/22:0, d18:1/22:1, d18:1/24:0, d18:1/24:1) were positively associated with incident T2DM. Among them, Cer(d18:1/24:0) showed the strongest association with increased T2DM risk (OR = 2.17 (95% CI: 1.29,3.66, P-trend < 0.05). Additionally, the ratios of Cer(d18:1/18:0)/Cer(d18:1/16:0) and Cer(d18:1/20:0)/Cer(d18:1/16:0) were significantly associated with T2DM risk, and adjusted ORs for the highest vs. lowest quartiles were 2.11 (95% CI: 1.27,3.51), and 1.69 (95% CI: 1.04,2.76), respectively (all P-trend < 0.05). The addition of individual ceramides or ceramide ratios to conventional risk factors significantly improved the discrimination and risk reclassification (all P < 0.05).
conclusionsDistinct plasma ceramides are associated with the T2DM risk and Cer(d18:1/24:0) serves as the strongest predictive marker. Moreover, the ratios of Cer(d18:1/18:0)/Cer(d18:1/16:0) and Cer(d18:1/20:0)/Cer(d18:1/16:0) are also particularly robust independent predictors of incident T2DM. Ceramides and their ratios can be used to identify high-risk patients with T2DM, providing targets for the primary and secondary prevention of T2DM.
Indexed as
Identifiers
42550223What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.